Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,420 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06359509 | Study of SYS6020 in BCMA-positive Multiple Myeloma | not yet recruiting | Early Phase 1 | 10 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Apr 11, 2024 | clinicaltrials |
| NCT05013437 | Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma(AHCT) | withdrawn | Early Phase 1 | 0 | Koen van BesienOTHER |
| 1 |
| Apr 2, 2024 |
| clinicaltrials |
| NCT06298266 | To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma | not yet recruiting | Early Phase 1 | 15 | Guangdong Second Provincial General HospitalOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT05840107 | Study of FasT CAR-T GC012F Injection NDMM Patients | unknown | Early Phase 1 | 18 | Shanghai Changzheng HospitalOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT05643248 | To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects | completed | Early Phase 1 | 9 | Nanexa ABINDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT06067581 | the Safety and Efficacy of SENL103 Autologous T Cell Injection | unknown | Early Phase 1 | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Oct 5, 2023 | clinicaltrials |
| NCT06045091 | To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL | recruiting | Early Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03591614 | Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma | withdrawn | Early Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT03272633 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies | terminated | Early Phase 1 | 2 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT03371420 | PET Imaging of Subjects Using 124I-PU-AD | terminated | Early Phase 1 | 5 | Samus Therapeutics, Inc.INDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05655676 | 89Zr-labeled NY008 PET Imaging in Patients | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Dec 19, 2022 | clinicaltrials |
| NCT05652530 | Clinical Study of the Safety and Efficacy of BCMA CAR-NK | unknown | Early Phase 1 | 19 | Shenzhen Pregene Biopharma Co., Ltd.INDUSTRY | 1 | Dec 15, 2022 | clinicaltrials |
| NCT02851056 | Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT) | completed | Early Phase 1 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT05016778 | A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma | unknown | Early Phase 1 | 15 | Zhejiang UniversityOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT05478343 | Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma | unknown | Early Phase 1 | 10 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Jul 28, 2022 | clinicaltrials |
| NCT05430945 | A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | unknown | Early Phase 1 | 100 | Zhejiang UniversityOTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT04657861 | APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma | recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT05364177 | 68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT05008536 | Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma | unknown | Early Phase 1 | 27 | Xinqiao Hospital of ChongqingOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT04662294 | CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases | recruiting | Early Phase 1 | 108 | Zhejiang UniversityOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT04617704 | BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma | unknown | Early Phase 1 | 15 | Shanghai Changzheng HospitalOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT03943472 | BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma | unknown | Early Phase 1 | 10 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Aug 31, 2021 | clinicaltrials |
| NCT04236011 | BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma | unknown | Early Phase 1 | 15 | Shanghai Changzheng HospitalOTHER | 1 | Jun 15, 2021 | clinicaltrials |
| NCT04670055 | A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | not yet recruiting | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT04541368 | A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy | not yet recruiting | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT04650724 | Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor | completed | Early Phase 1 | 3 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 3, 2020 | clinicaltrials |
| NCT04637269 | Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma | unknown | Early Phase 1 | 16 | Xinqiao Hospital of ChongqingOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT04626752 | CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma | unknown | Early Phase 1 | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04603872 | CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies | recruiting | Early Phase 1 | 120 | Zhejiang UniversityOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT04412889 | A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM | unknown | Early Phase 1 | 18 | Hebei Yanda Ludaopei HospitalOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT03173430 | Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma | terminated | Early Phase 1 | 6 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT03436342 | Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT04191941 | Treatment of Hematological Malignancy With Novel CAR-T Cells. | unknown | Early Phase 1 | 9 | Timmune Biotech Inc.INDUSTRY | 1 | Dec 10, 2019 | clinicaltrials |
| NCT04186052 | Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma | unknown | Early Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 4, 2019 | clinicaltrials |
| NCT04182581 | A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma | unknown | Early Phase 1 | 18 | Xijing HospitalOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT04156269 | BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma | unknown | Early Phase 1 | 12 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01594242 | Autophagy Induction After Bortezomib for Myeloma | completed | Early Phase 1 | 11 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT01286675 | Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT | completed | Early Phase 1 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 1, 2019 | clinicaltrials |
| NCT01861340 | Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma | completed | Early Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT03661554 | BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma(BCMA CAR-T) | unknown | Early Phase 1 | 15 | The Pregene (ShenZhen) Biotechnology Company, Ltd.INDUSTRY | 1 | Sep 10, 2018 | clinicaltrials |
| NCT02971410 | Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Early Phase 1 | 0 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT03559764 | Study of BCMA CAR-T in Multiple Myeloma | unknown | Early Phase 1 | 20 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 0 | Jun 18, 2018 | clinicaltrials |
| NCT02447055 | Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma | withdrawn | Early Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Jul 12, 2016 | clinicaltrials |
| NCT02109861 | Microdose Study of Melphalan, Bortezomib and Dexamethasone(Phase-0-MM) | unknown | Early Phase 1 | 6 | Henrik GregersenOTHER | 1 | Dec 8, 2015 | clinicaltrials |
| NCT02117115 | Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation(GVHD) | completed | Early Phase 1 | 21 | Washington University School of MedicineOTHER | 1 | Jun 11, 2015 | clinicaltrials |
| NCT01537861 | Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma | terminated | Early Phase 1 | 7 | Washington University School of MedicineOTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT01396200 | Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine | completed | Early Phase 1 | 6 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 26, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Apr 11, 2024source: clinicaltrials